Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Warfarin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VKORC1 known ✓ | Q9BQB6 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 10/20 | 1.00 |
| ▸ | ALB | P02768 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | PCSK7 | Q16549 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.77 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | BRD4 | O60885 | 1/20 | 0.68 |
| ▸ | NQO1 | P15559 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Warfarin SCHEMBL3792087 | 1.00 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL29400364 | 1.00 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL3689 | 1.00 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL2139452 | 1.00 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL4439794 | 1.00 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL4757598 | 0.99 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL34347 | 0.99 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL2597774 | 0.99 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL13278154 | 0.99 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL5016404 | 0.99 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 518 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101983-A1 | NON-STEROIDAL ISONITRILE BINDING COMPOUNDS OF CYTOCHROME P450 SUBTYPES | BRANDEIS UNIVERSITY (US) | 2025-05-15 | — | — | WO | claimed |
| CN-119541900-A | Evaluation method for influence of traditional Chinese medicine on warfarin anticoagulation effect based on PK/PD theory | 哈尔滨医科大学 | 2025-02-28 | — | — | CN | claimed |
| US-20240100126-A1 | Methods Comprising Continuous Administration of a GLP-1 Receptor Agonist and Co-administration of a Drug | I2O THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | claimed |
| US-10835580-B2 | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug | INTARCIA THERAPEUTICS, INC. (US) | 2020-11-17 | — | — | US | claimed |
| EP-3565580-A1 | METHODS COMPRISING CONTINUOUS ADMINISTRATION OF A GLP-1 RECEPTOR AGONIST AND CO-ADMINSTRATION OF A DRUG | Intarcia Therapeutics, Inc (US) | 2019-11-13 | — | — | EP | claimed |
| WO-2018129058-A1 | METHODS COMPRISING CONTINUOUS ADMINISTRATION OF A GLP-1 RECEPTOR AGONIST AND CO-ADMINSTRATION OF A DRUG | INTARCIA THERAPEUTICS, INC. (US) | 2018-07-12 | — | — | WO | claimed |
| US-20180185451-A1 | Methods Comprising Continuous Administration of a GLP-1 Receptor Agonist and Co-administration of a Drug | INTARCIA THERAPEUTICS, INC. | 2018-07-05 | — | — | US | claimed |
| WO-2017140840-A1 | DETERMINATION OF CORRECTED DERIVED FIBRINOGEN RESULTS | ROCHE DIAGNOSTICS GMBH (DE) | 2017-08-24 | — | — | WO | claimed |
| EP-1603548-A4 | METHOD AND COMPOSITION FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS INC (US) | 2007-10-10 | — | — | EP | claimed |
| WO-2007094825-A2 | METAXALONE PRODUCTS, METHOD OF MANUFACTURE, AND METHOD OF USE | MUTUAL PHARMACEUTICAL COMPANY, INC. (US) | 2007-08-23 | — | — | WO | claimed |
| US-20060116826-A1 | Crystals of cytochrome P450 2C9, structures thereof and their use | ASTEX THERAPEUTICS LIMITED (GB) | 2006-06-01 | — | — | US | claimed |
| EP-1623024-A2 | CRYSTALS OF CYTOCHROME P450 2C9, STRUCTURES THEREOF AND THEIR USE | Astex Therapeutics Limited (GB) | 2006-02-08 | — | — | EP | claimed |
| US-20050288375-A1 | Method and composition for treating neurodegenerative disorders | MYRIAD GENETICS, INCORPORATED (US) | 2005-12-29 | — | — | US | claimed |
| EP-1603548-A2 | METHOD AND COMPOSITION FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2005-12-14 | — | — | EP | claimed |
| WO-2004096857-A2 | CRYSTALS OF CYTOCHROME P450 2C9, STRUCTURES THEREOF AND THEIR USE | ASTEX THERAPEUTICS LIMITED (GB) | 2004-11-11 | — | — | WO | claimed |
| WO-2004071431-A2 | METHOD AND COMPOSITION FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2004-08-26 | — | — | WO | claimed |
| US-20040053383-A1 | Crystals of cytochrome P450 2C9, structures thereof and their use | ASTEX TECHNOLOGY LTD. (GB) | 2004-03-18 | — | — | US | claimed |
| WO-2000043003-A1 | THE THERAPEUTIC USE OF R-WARFARIN AS ANTICOAGULANT | DARWIN DISCOVERY LIMITED (GB) | 2000-07-27 | — | — | WO | claimed |
| US-5856525-A | ANTICOAGULANTS; RACEMIC MIXTURE OF S AND R-WARFARIN | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-01-05 | — | — | US | claimed |
| US-20250302817-A1 | METHODS FOR TREATING PTEN-MUTANT TUMORS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-10-02 | — | — | US | disclosed |
| EP-3664791-B1 | EPLERENONE FOR PHENOTYPING OF CYP3A5 ENZYME ACTIVITY IN SALIVA SAMPLES | CU VENTURES INC (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250276120-A1 | METHOD FOR PREVENTING COAGULATION IN PATIENTS WITH IMPLANTED CARDIAC DEVICES | Cadrenal Therapeutics, Inc. | 2025-09-04 | — | — | US | disclosed |
| US-20250230481-A1 | Compositions for CYP450 Phenotyping Using Saliva Samples | CONCORDIA UNIVERSITY, INC. | 2025-07-17 | — | — | US | disclosed |
| EP-3443338-B1 | METHODS FOR DETECTION OF SAMPLE ENANTIOMERS USING DIFFERENTIAL MOBILITY SPECTROMETRY | DH TECHNOLOGIES DEV PTE LTD (SG) | 2025-07-09 | — | — | EP | disclosed |
| CN-113365623-B | Antiandrogens for the treatment of metastatic castration-sensitive prostate cancer | 阿拉贡药品公司 | 2025-06-24 | — | — | CN | disclosed |
| US-12303497-B2 | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| WO-2025101983-A1 | NON-STEROIDAL ISONITRILE BINDING COMPOUNDS OF CYTOCHROME P450 SUBTYPES | BRANDEIS UNIVERSITY (US) | 2025-05-15 | — | — | WO | disclosed |
| CN-119541900-A | Evaluation method for influence of traditional Chinese medicine on warfarin anticoagulation effect based on PK/PD theory | 哈尔滨医科大学 | 2025-02-28 | — | — | CN | disclosed |
| CN-119136793-A | Bile acids and phenylbutyric acid with CYP P450 or transporter substrates for the treatment of amyotrophic lateral sclerosis | 艾米利克斯制药公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-4438126-A2 | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | Aragon Pharmaceuticals, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118678956-A | Methods of treating sickle cell disease using Wo Sailuo torr | 全球血液疗法公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20240299409-A1 | TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS | BioAxone BioSciences, Inc. (US) | 2024-09-12 | — | — | US | disclosed |
| EP-4426300-A2 | METHODS OF ADMINISTERING VOXELOTOR | Global Blood Therapeutics, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-4365306-A9 | METHODS FOR DETECTING TARGET POLYNUCLEOTIDES | NunaBio Limited (GB) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024137821-A1 | EFFECT OF RIVOCERANIB ON CYTOCHROME P450 ENZYME SUBSTRATES | ELEVAR THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-118203659-A | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor | 瑞泽恩制药公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240165091-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | ARAGON PHARMACEUTICALS INC (US) | 2024-05-23 | — | — | US | disclosed |
| EP-4365306-A2 | METHODS FOR DETECTING TARGET POLYNUCLEOTIDES | NunaBio Limited (GB) | 2024-05-08 | — | — | EP | disclosed |
| US-20240139211-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | AMYLYX PHARMACEUTICALS, INC. | 2024-05-02 | — | — | US | disclosed |
| US-11963952-B2 | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240123024-A1 | ORAL OCTREOTIDE THERAPY AND CONTRACEPTIVE METHODS | AMRYT ENDO INC (US) | 2024-04-18 | — | — | US | disclosed |
| WO-2024072778-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | AMYLYX PHARMACEUTICALS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-4345110-A2 | METHODS FOR TREATING SEVERE ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R INHIBITOR | Regeneron Pharmaceuticals, Inc. (US) | 2024-04-03 | — | — | EP | disclosed |
| US-20240100126-A1 | Methods Comprising Continuous Administration of a GLP-1 Receptor Agonist and Co-administration of a Drug | I2O THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20240100033-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer | ARAGON PHARMACEUTICALS INC (US) | 2024-03-28 | — | — | US | disclosed |
| EP-3759253-B1 | METHODS FOR DETECTING TARGET POLYNUCLEOTIDES | NUNABIO LTD (GB) | 2024-03-27 | — | — | EP | disclosed |
| CN-109963577-B | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor | 瑞泽恩制药公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-3565580-B1 | CONTINUOUS ADMINISTRATION OF EXENATIDE AND CO-ADMINSTRATION OF ACETAMINOPHEN, ETHINYLESTRADIOL OR LEVONORGESTREL | I2O THERAPEUTICS INC (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4326720-A1 | PARP1 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-11903937-B2 | — | — | 2024-02-20 | — | — | US | disclosed |
| EP-3515465-B1 | METHODS FOR TREATING SEVERE ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R INHIBITOR | REGENERON PHARMA (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11890316-B2 | Oral octreotide therapy and contraceptive methods | AMRYT ENDO, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| CN-117177972-A | PARP1 inhibitors and uses thereof | 新特拉有限公司 | 2023-12-05 | — | — | CN | disclosed |
| WO-2023209555-A1 | APPROVED DRUG PRODUCTS AND METHODS FOR TREATING PROSTATE CANCER | ARAGON PHARMACEUTICALS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230277630-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | AMYLYX PHARMACEUTICALS, INC. | 2023-09-07 | — | — | US | disclosed |
| WO-2023168280-A1 | A BILE ACID AND A PHENYLBUTYRATE WITH CYP P450 OR TRANSPORTER SUBSTRATES FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | AMYLYX PHARMACEUTICALS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-11747352-B2 | Eplerenone for phenotyping of CYP3A5 enzyme activity in saliva samples | CONCORDIA UNIVERSITY, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230233555-A1 | METHOD OF ADMINISTERING UPADACITINIB TO AVOID ADVERSE DRUG INTERACTIONS AND EFFECTS | ABBVIE INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-11701366-B2 | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors | BioAxone BioSciences, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230190722-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | ARAGON PHARMACEUTICALS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-11654183-B2 | Methods comprising continuous administration of exenatide and co-administration of a drug | INTARCIA THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| EP-4178616-A1 | SAFE AND EFFECTIVE METHOD OF TREATING PSORIATIC ARTHRITIS WITH ANTI-IL23 SPECIFIC ANTIBODY | Janssen Biotech, Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| CN-110088628-B | Determination of interferents in a sample | 豪夫迈·罗氏有限公司 | 2023-05-16 | — | — | CN | disclosed |
| WO-2023081801-A2 | METHODS OF ADMINISTERING VOXELOTOR | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-04-27 | — | — | US | disclosed |
| CN-115896271-A | Kit for detecting related genotype of warfarin gene and preparation method thereof | 首都医科大学附属北京安贞医院 | 2023-04-04 | — | — | CN | disclosed |
| US-11591331-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-20230022446-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer | ARAGON PHARMACEUTICALS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230015823-A1 | METHODS OF ADMINISTERING VOXELOTOR | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| CN-111004811-B | CYP2C9 gene segment containing 637A > | 北京医院 | 2022-12-30 | — | — | CN | disclosed |
| CN-111004810-B | CYP2C9 gene segment containing 419G > | 北京医院 | 2022-12-27 | — | — | CN | disclosed |
| US-11491149-B2 | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220348574-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2022-11-03 | — | — | US | disclosed |
| CN-115253991-A | Modular system for performing multi-step chemical reactions and methods of use thereof | 斯坦福国际研究院 | 2022-11-01 | — | — | CN | disclosed |
| WO-2022225934-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| EP-4061368-A1 | METHODS OF ADMINISTERING VOXELOTOR | Global Blood Therapeutics, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |
| US-20220280510-A1 | MOCETINOSTAT IN COMBINATION WITH CHEMOTHERAPY TO TREAT RHABDOMYOSARCOMA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220243250-A1 | DETERMINATION OF INTERFERENTS IN A SAMPLE | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220233633-A1 | ORAL OCTREOTIDE THERAPY AND CONTRACEPTIVE METHODS | AMRYT PHARMACEUTICALS INC. | 2022-07-28 | — | — | US | disclosed |
| US-20220211690-A1 | METHODS FOR TREATING PTEN-MUTANT TUMORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-07-07 | — | — | US | disclosed |
| CN-110650797-B | Modular system for performing multi-step chemical reactions and methods of use thereof | 斯坦福国际研究院 | 2022-07-01 | — | — | CN | disclosed |
| US-20220160695-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | ARAGON PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220110999-A1 | METHODS FOR TREATING SEVERE ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R INHIBITOR | REGENERON PHARMACEUTICALS, INC., | 2022-04-14 | — | — | US | disclosed |
| CN-114231606-A | Method for rapidly analyzing CYP2C9 genotype | 北京艾迪康医学检验实验室有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20220054468-A9 | Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer | ARAGON PHARMACEUTICALS, INC. | 2022-02-24 | — | — | US | disclosed |
| WO-2022013745-A1 | SAFE AND EFFECTIVE METHOD OF TREATING PSORIATIC ARTHRITIS WITH ANTI-IL23 SPECIFIC ANTIBODY | JANSSEN BIOTECH, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| US-11215583-B2 | Methods for detection of sample enantiomers using differential mobility spectrometry | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2022-01-04 | — | — | US | disclosed |
| US-20210401998-A1 | METHODS OF TREATING CYP2D6 ALTERNATIVE METABOLIZERS | NEKTAR THERAPEUTICS (US) | 2021-12-30 | — | — | US | disclosed |
| EP-3917519-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | Aragon Pharmaceuticals, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| CN-108570498-B | Primer probe composition and kit for detecting human CYP2C9 and VKORC1 gene polymorphism and application | 山东维真生物科技有限公司 | 2021-11-23 | — | — | CN | disclosed |
| US-11167004-B2 | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor | REGENERON PHARMACEUTICALS, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-11160796-B2 | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-11141457-B1 | Oral octreotide therapy and contraceptive methods | AMRYT ENDO, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| CN-113365623-A | Antiandrogen for treating metastatic castration sensitive prostate cancer | 阿拉贡药品公司 | 2021-09-07 | — | — | CN | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20210236602-A1 | Methods Comprising Continuous Administration of a GLP-1 Receptor Agonist and Co-administration of a Drug | INTARCIA THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-11033631-B2 | Methods of treating CYP2D6 alternative metabolizers | NEKTAR THERAPEUTICS (US) | 2021-06-15 | — | — | US | disclosed |
| WO-2021101910-A1 | METHODS OF ADMINISTERING VOXELOTOR | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210139945-A1 | COMPOSITIONS FOR CYP450 PHENOTYPING USING SALIVA SAMPLES | CU Ventures, Inc. | 2021-05-13 | — | — | US | disclosed |
| US-20210093620-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer | ARAGON PHARMACEUTICALS, INC. | 2021-04-01 | — | — | US | disclosed |
| EP-3555632-B1 | DETERMINATION OF BILIRUBIN IN A SAMPLE | ROCHE DIAGNOSTICS GMBH (DE) | 2021-03-10 | — | — | EP | disclosed |
| CN-112458158-A | CYP2C9 gene segment containing 373C > T mutation, protein segment coded by same and application thereof | 杨杰孚 | 2021-03-09 | — | — | CN | disclosed |
| US-10927398-B2 | Compositions for CYP450 phenotyping using saliva samples | CONCORDIA UNIVERSITY INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200371123-A1 | Eplerenone for Phenotyping of CYP3A5 Enzyme Activity in Saliva Samples | CU Ventures, Inc. | 2020-11-26 | — | — | US | disclosed |
| US-20200360361-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer | ARAGON PHARMACEUTICALS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-10835580-B2 | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug | INTARCIA THERAPEUTICS, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200352926-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer | ARAGON PHARMACEUTICALS INC (US) | 2020-11-12 | — | — | US | disclosed |
| US-10806794-B2 | Protease inhibitors having enhanced features | NEKTAR THERAPEUTICS (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3697398-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | Aragon Pharmaceuticals, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200246416-A1 | METHODS FOR TREATING SEVERE ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R INHIBITOR | SANOFI BIOTECHNOLOGY (FR) | 2020-08-06 | — | — | US | disclosed |
| WO-2020157699-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | ARAGON PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| CN-111479560-A | Antiandrogen for treating non-metastatic castration-resistant prostate cancer | 阿拉贡药品公司 | 2020-07-31 | — | — | CN | disclosed |
| US-10702508-B2 | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| EP-3664791-A1 | EPLERENONE FOR PHENOTYPING OF CYP3A5 ENZYME ACTIVITY IN SALIVA SAMPLES | Concordia University, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| CN-111172253-A | Kit and method for detecting CYP2C9 and VKORC1 gene polymorphism in one tube manner | 上海未凡生物科技有限公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-111118144-A | Kit for simultaneously detecting CYP2C9 and VKORC1 genes and application thereof | 广东药科大学 | 2020-05-08 | — | — | CN | disclosed |
| CN-111004811-A | CYP2C9 gene segment containing 637A > G mutation, protein segment coded by same and application thereof | 蔡剑平 | 2020-04-14 | — | — | CN | disclosed |
| CN-111004810-A | CYP2C9 gene segment containing 419G > A mutation, coded protein segment and application thereof | 蔡剑平 | 2020-04-14 | — | — | CN | disclosed |
| CN-110872611-A | Method for synchronously detecting metabolic gene polymorphism of warfarin | 西安和合医学检验所有限公司 | 2020-03-10 | — | — | CN | disclosed |
| CN-110819709-A | Method for detecting CYP2C9 and VKORC1 gene polymorphism by fluorescent quantitative PCR (polymerase chain reaction) | 北京和合医学诊断技术股份有限公司 | 2020-02-21 | — | — | CN | disclosed |
| US-10485844-B2 | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor | REGENERON PHARMACEUTICALS, INC. (US) | 2019-11-26 | — | — | US | disclosed |
| EP-3565580-A1 | METHODS COMPRISING CONTINUOUS ADMINISTRATION OF A GLP-1 RECEPTOR AGONIST AND CO-ADMINSTRATION OF A DRUG | Intarcia Therapeutics, Inc (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3555632-A1 | DETERMINATION OF INTERFERENTS IN A SAMPLE | Roche Diagnostics GmbH (DE) | 2019-10-23 | — | — | EP | disclosed |
| US-20190276872-A1 | DETERMINATION OF INTERFERENTS IN A SAMPLE | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190264252-A1 | COMPOSITIONS FOR CYP450 PHENOTYPING USING SALIVA SAMPLES | CONCORDIA UNIVERSITY, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190252050-A1 | METHOD FOR PROVIDING CURRENT ASSESSMENTS OF GENETIC RISK | NATIONAL BIOMEDICAL RESEARCH FOUNDATION (US) | 2019-08-15 | — | — | US | disclosed |
| EP-3515465-A1 | METHODS FOR TREATING SEVERE ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R INHIBITOR | Regeneron Pharmaceuticals, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| CN-109963577-A | Method for treating severe atopic dermatitis by administering an IL-4R inhibitor | 瑞泽恩制药公司 | 2019-07-02 | — | — | CN | disclosed |
| US-20190192501-A1 | METHODS FOR TREATING PTEN-MUTANT TUMORS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190137447-A1 | METHODS FOR DETECTION OF SAMPLE ENANTIOMERS USING DIFFERENTIAL MOBILITY SPECTROMETRY | DH TECHNOLOGIES DEV PTE LTD (SG) | 2019-05-09 | — | — | US | disclosed |
| WO-2019078920-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | ARAGON PHARMACEUTICALS, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
| US-20190111036-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | ARAGON PHARMACEUTICALS, INC. | 2019-04-18 | — | — | US | disclosed |
| EP-3443338-A1 | METHODS FOR DETECTION OF SAMPLE ENANTIOMERS USING DIFFERENTIAL MOBILITY SPECTROMETRY | DH Technologies Development PTE. Ltd. (SG) | 2019-02-20 | — | — | EP | disclosed |
| WO-2019032589-A1 | EPLERENONE FOR PHENOTYPING OF CYP3A5 ENZYME ACTIVITY IN SALIVA SAMPLES | CONCORDIA UNIVERSITY, INC. (US) | 2019-02-14 | — | — | WO | disclosed |
| US-20180353609-A1 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | NEKTAR THERAPEUTICS | 2018-12-13 | — | — | US | disclosed |
| EP-3384040-A1 | COMPOSITIONS FOR CYP450 PHENOTYPING USING SALIVA SAMPLES | Concordia University, Inc. (US) | 2018-10-10 | — | — | EP | disclosed |
| US-10092656-B2 | Protease inhibitors having enhanced features | NEKTAR THERAPEUTICS (US) | 2018-10-09 | — | — | US | disclosed |
| CN-108570498-A | Primer combination of probe object, kit and application for detecting mankind's CYP2C9 and VKORC1 gene pleiomorphism | 山东维真生物科技有限公司 | 2018-09-25 | — | — | CN | disclosed |
| EP-2608784-B1 | TREATMENT OR PREVENTION OF HEART FAILURE IN A MAMMAL RECEIVING ANTI-COAGULANT THERAPY | NOVARTIS AG (CH) | 2018-09-19 | — | — | EP | disclosed |
| WO-2018142288-A1 | MUKAADIAL ACETATE ISOLATED FROM WARBURGIA SALUTARIS AND THE USE THEREOF AS AN ANTIMALARIAL | UNIVERSITY OF KWAZULU-NATAL (ZA) | 2018-08-09 | — | — | WO | disclosed |
| EP-2659404-B1 | CELLS HAVING DISRUPTED EXPRESSION OF PROTEINS INVOLVED IN ADME AND TOXICOLOGY PROCESSES | SIGMA ALDRICH CO LLC (US) | 2018-08-08 | — | — | EP | disclosed |
| WO-2018129058-A1 | METHODS COMPRISING CONTINUOUS ADMINISTRATION OF A GLP-1 RECEPTOR AGONIST AND CO-ADMINSTRATION OF A DRUG | INTARCIA THERAPEUTICS, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| US-20180185451-A1 | Methods Comprising Continuous Administration of a GLP-1 Receptor Agonist and Co-administration of a Drug | INTARCIA THERAPEUTICS, INC. | 2018-07-05 | — | — | US | disclosed |
| WO-2018109004-A1 | DETERMINATION OF INTERFERENTS IN A SAMPLE | ROCHE DIAGNOSTICS GMBH (DE) | 2018-06-21 | — | — | WO | disclosed |
| US-9986723-B2 | Screen and use of therapeutics for pancreatic ductal adenocarcinoma | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-06-05 | — | — | US | disclosed |
| WO-2018057776-A1 | METHODS FOR TREATING SEVERE ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R INHIBITOR | REGENERON PHARMACEUTICALS, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| US-20180078603-A1 | Methods for Treating Severe Atopic Dermatitis by Administering an IL-4R Inhibitor | SANOFI BIOTECHNOLOGY (FR) | 2018-03-22 | — | — | US | disclosed |
| WO-2018038886-A1 | METHODS FOR TREATING PTEN-MUTANT TUMORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-03-01 | — | — | WO | disclosed |
| WO-2017178988-A1 | METHODS FOR DETECTION OF SAMPLE ENANTIOMERS USING DIFFERENTIAL MOBILITY SPECTROMETRY | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017140840-A1 | DETERMINATION OF CORRECTED DERIVED FIBRINOGEN RESULTS | ROCHE DIAGNOSTICS GMBH (DE) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017095921-A1 | COMPOSITIONS FOR CYP450 PHENOTYPING USING SALIVA SAMPLES | CONCORDIA UNIVERSITY INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| US-20170076037-A1 | METHOD FOR INCREASING UTILIZATION OF GENETIC TESTING | NATIONAL BIOMEDICAL RESEARCH FOUNDATION (US) | 2017-03-16 | — | — | US | disclosed |
| EP-3125939-A1 | USE OF A FACTOR XA INHIBITOR FOR TREATING AND PREVENTING BLEEDING EVENTS AND RELATED DISORDERS IN PATIENTS HAVING SENSITIVITY TO VITAMIN K ANTAGONISTS USED AS ANTICOAGULANTS | Daiichi Sankyo Co., Ltd. (JP) | 2017-02-08 | — | — | EP | disclosed |
| US-20170028077-A1 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | NEKTAR THERAPEUTICS | 2017-02-02 | — | — | US | disclosed |
| CN-103173443-B | Including 1300A > T sudden change CYP2C9 genetic fragment, coded protein fragments and application thereof | 卫生部北京医院 | 2016-08-24 | — | — | CN | disclosed |
| CN-105861688-A | Primer combination, reagent kit and method for detecting CYP4F2*3 | 北京晋祺生物科技有限公司 | 2016-08-17 | — | — | CN | disclosed |
| WO-2015150950-A9 | USE OF A FACTOR XA INHIBITOR FOR TREATING AND PREVENTING BLEEDING EVENTS AND RELATED DISORDERS IN PATIENTS HAVING SENSITIVITY TO VITAMIN K ANTAGONISTS USED AS ANTICOAGULANTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-07-14 | — | — | WO | disclosed |
| CN-103031319-B | Including the CYP2C9 genetic fragment of 371G > A sudden change, coded protein fragments and application thereof | 蔡剑平 | 2016-06-29 | — | — | CN | disclosed |
| CN-103031321-B | Including the CYP2C9 genetic fragment of 896C > G sudden change, coded protein fragments and application thereof | 蔡剑平 | 2016-06-22 | — | — | CN | disclosed |
| CN-103194464-B | Including the CYP2C9 genetic fragment of 1400T > C sudden change, coded protein fragments and application thereof | 卫生部北京医院 | 2016-06-22 | — | — | CN | disclosed |
| CN-105603059-A | CYP4F2 gene detection primer group, reaction system composed thereof and application | BEIJING JINQI BIOTECHNOLOGY CO LTD | 2016-05-25 | — | — | CN | disclosed |
| CN-103031318-B | Comprise the CYP2C9 genetic fragment of 445G > A sudden change, coded protein fragments and application thereof | HU GUOXIN (CN) | 2016-05-18 | — | — | CN | disclosed |
| US-20160128311-A1 | SCREEN AND USE OF THERAPEUTICS FOR PANCREATIC DUCTAL ADENOCARCINOMA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-05-12 | — | — | US | disclosed |
| CN-103031320-B | Comprise the CYP2C9 gene fragment of 329T > C sudden change, coded protein fragments and application thereof | CAI JIANPING (CN) | 2016-03-30 | — | — | CN | disclosed |
| CN-105368826-A | Primer pair for detecting CYP2C9 genetic typing through pyrosequencing method and kit | CHANGSHA 3G BIOTECH CO LTD | 2016-03-02 | — | — | CN | disclosed |
| US-9255256-B2 | Expression of functional cytochorome P450 monooxygenase system in enterobacteria | BTG INTERNATIONAL LIMITED | 2016-02-09 | — | — | US | disclosed |
| CN-105274220-A | CYP4F2 x 3 detection primer and detection system thereof | BEIJING PUQI BIOLOG TECHNOLOGY CO LTD | 2016-01-27 | — | — | CN | disclosed |
| CN-105274228-A | Kit and method for warfarin medicine gene mutation site detection | SHANGHAI OUTDO BIOTECH CO LTD | 2016-01-27 | — | — | CN | disclosed |
| CN-105177116-A | Human CYP2C9 and VKORC1 genetic polymorphism detection kit | WUHAN YZY MEDICAL TECHNOLOGY CO LTD | 2015-12-23 | — | — | CN | disclosed |
| CN-103045617-B | Comprise the CYP2C9 gene fragment of 1081C > A sudden change, coded protein fragments and application thereof | CAI JIANPING (CN) | 2015-11-25 | — | — | CN | disclosed |
| CN-103031314-B | Comprise the CYP2C9 gene fragment of 389C > T sudden change, coded protein fragments and application thereof | CAI JIANPING (CN) | 2015-11-25 | — | — | CN | disclosed |
| CN-103031311-B | Comprise the CYP2C9 gene fragment of 679C > T sudden change, coded protein fragments and application thereof | CAI JIANPING (CN) | 2015-11-25 | — | — | CN | disclosed |
| CN-103031312-B | Comprise the CYP2C9 gene fragment of 488C > T sudden change, coded protein fragments and application thereof | CAI JIANPING (CN) | 2015-11-25 | — | — | CN | disclosed |
| CN-103194463-B | Comprise the CYP2C9 gene fragment of 1009C > A sudden change, coded protein fragments and application thereof | BEIJING HOSPITAL (CN) | 2015-11-18 | — | — | CN | disclosed |
| CN-105018583-A | Kit used for detecting polymorphism of genes related to Warfarin and Clopidogrel personalized medication and application thereof | CAPITALBIO CORP | 2015-11-04 | — | — | CN | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| CN-104975069-A | Kit and method for determining genotype of predetermined SNP (single nucleotide polymorphisms) locus of DNA (deoxyribonucleic acid) sample to be detected | HUBEI VIDAGEN GENE TECHNOLOGY CO LTD | 2015-10-14 | — | — | CN | disclosed |
| WO-2015150950-A1 | USE OF A FACTOR XA INHIBITOR FOR TREATING AND PREVENTING BLEEDING EVENTS AND RELATED DISORDERS IN PATIENTS HAVING SENSITIVITY TO VITAMIN K ANTAGONISTS USED AS ANTICOAGULANTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-08 | — | — | WO | disclosed |
| US-20150272935-A1 | Use of a Factor Xa Inhibitor for Treating and Preventing Bleeding Events And Related Disorders in Patients Having Sensitivity to Vitamin K Antagonists Used As Anticoagulants | DAIICHI SANKYO, INC. | 2015-10-01 | — | — | US | disclosed |
| CN-103045619-B | Comprise the CYP2C9 gene fragment of 293G > T sudden change, coded protein fragments and application thereof | CAI JIANPING (CN) | 2015-09-16 | — | — | CN | disclosed |
| CN-103045615-B | Comprise the CYP2C9 gene fragment of 146A > G sudden change, coded protein fragments and application thereof | HU GUOXIN (CN) | 2015-09-16 | — | — | CN | disclosed |
| CN-103031317-B | Comprise the CYP2C9 gene fragment of 287G>C sudden change, coded protein fragments and application thereof | CAI JIANPING (CN) | 2015-09-09 | — | — | CN | disclosed |
| CN-103045616-B | Comprise the CYP2C9 gene fragment of 620T > C sudden change, coded protein fragments and application thereof | CAI JIANPING (CN) | 2015-08-26 | — | — | CN | disclosed |
| CN-103045618-B | Comprise the CYP2C9 gene fragment of 394C > T sudden change, coded protein fragments and application thereof | CAI JIANPING (CN) | 2015-08-26 | — | — | CN | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| CN-103031316-B | CYP2C9 gene segment comprising 1029C>A, coded protein segment and application thereof | CAI JIANPING | 2015-07-01 | — | — | CN | disclosed |
| US-20150164485-A1 | DNA MEDICATED COLLECTION KITS | ASCLEMED USA, INC. dba EnovaChem Manufacturing (US) | 2015-06-18 | — | — | US | disclosed |
| CN-104711344-A | Warfarin individualized medication gene detection kit and application thereof | YANG GUOPING | 2015-06-17 | — | — | CN | disclosed |
| CN-103031313-B | CYP2C9 gene segment comprising 370C>T, coded protein segment and application thereof | CAI JIANPING | 2015-06-17 | — | — | CN | disclosed |
| US-20150012286-A1 | INSTRUMENTS AND METHODS FOR OBTAINING INFORMED CONSENT TO GENETIC TESTS | NAT BIOMEDICAL RES FOUNDATION (US) | 2015-01-08 | — | — | US | disclosed |
| CN-102281758-B | Mouse having human hepatocytes transplanted therein | CENTRAL INST EXPER ANIMALS | 2014-12-10 | — | — | CN | disclosed |
| WO-2014193589-A1 | CANCER TREATMENT METHOD | GLAXOSMITHKLINE LLC (US) | 2014-12-04 | — | — | WO | disclosed |
| US-20140329872-A1 | TREATMENT OF HYPERTENSION AND/OR PREVENTION OR TREATMENT OF HEART FAILURE IN A MAMMAL RECEIVING ANTI-COAGULANT THERAPY | NOVARTIS AG (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140323494-A1 | N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2014-10-30 | — | — | US | disclosed |
| US-20140249214-A1 | CO-ADMINISTRATION OF WARFARIN AND ETHYL EICOSAPENTAENOATE | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2014-09-04 | — | — | US | disclosed |
| EP-2194049-B1 | N-oxides of N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| US-8759402-B2 | Method to inhibit ischemia and reperfusion injury | RADICAL THERAPEUTIX (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2078029-B1 | ENANTIOMERICALLY PURE PHOSPHOINDOLE AS HIV INHIBITOR | IDENIX PHARMACEUTICALS INC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20140073762-A1 | MULTIPLE STATIONARY PHASE MATRIX AND USES THEREOF | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2014-03-13 | — | — | US | disclosed |
| WO-2014018375-A1 | CYP8B1 AND USES THEREOF IN THERAPEUTIC AND DIAGNOSTIC METHODS | XENON PHARMACEUTICALS INC. (CA) | 2014-01-30 | — | — | WO | disclosed |
| WO-2013190013-A1 | CELL OF HEPATOCYTE PHENOTYPE | WACLAWCZYK SIMON (DE) | 2013-12-27 | — | — | WO | disclosed |
| US-8608967-B2 | Multiple stationary phase matrix and uses thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2013-12-17 | — | — | US | disclosed |
| CN-103433073-A | (1R, 2R)-1, 2-diphenylethylenediamine grafted metal-organic framework catalyst, and preparation method and applications thereof | UNIV ZHEJIANG NORMAL | 2013-12-11 | — | — | CN | disclosed |
| EP-2111465-B1 | REAGENTS AND METHODS FOR DETECTING CYP2C9 POLYMORPHISMS | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2013-12-04 | — | — | EP | disclosed |
| US-20130316391-A1 | CELLS HAVING DISRUPTED EXPRESSION OF PROTEINS INVOLVED IN ADME AND TOXICOLOGY PROCESSES | Sigmaaldrich Co., LLC (US) | 2013-11-28 | — | — | US | disclosed |
| US-8586318-B2 | Restricted access media and methods for making restricted access media | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130297339-A1 | METHOD FOR INCREASING UTILIZATION OF GENETIC TESTING | NAT BIOMEDICAL RES FOUNDATION (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130297337-A1 | INSTRUMENTS AND METHODS FOR OBTAINING INFORMED CONSENT TO GENETIC TESTS | NAT BIOMEDICAL RES FOUNDATION (US) | 2013-11-07 | — | — | US | disclosed |
| EP-2659404-A2 | CELLS HAVING DISRUPTED EXPRESSION OF PROTEINS INVOLVED IN ADME AND TOXICOLOGY PROCESSES | Sigma-Aldrich Co., LLC (US) | 2013-11-06 | — | — | EP | disclosed |
| EP-2198052-B1 | METHOD FOR ADMINISTERING ANTICOAGULATION THERAPY | MARSHFIELD CLINIC (US) | 2013-07-17 | — | — | EP | disclosed |
| US-8486991-B2 | Enantiomerically pure phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| CN-103194463-A | CYP2C9 gene segment containing 1009C>A mutation, protein segment coded by same and application thereof | BEIJING HOSPITAL MINISTRY HEALTH | 2013-07-10 | — | — | CN | disclosed |
| CN-103194464-A | CYP2C9 gene segment containing 1400T>C mutation, protein segment coded by same and application thereof | BEIJING HOSPITAL MINISTRY HEALTH | 2013-07-10 | — | — | CN | disclosed |
| US-8483966-B1 | Method for increasing utilization of genetic testing | NATIONAL BIOMEDICAL RESEARCH FOUNDATION (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2608784-A1 | TREATMENT OF HYPERTENSION AND/OR PREVENTION OR TREATMENT OF HEART FAILURE IN A MAMMAL RECEIVING ANTI-COAGULANT THERAPY | Novartis AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| CN-103173443-A | CYP2C9 gene fragment containing 1300A>T mutation, protein fragment encoded through same and application thereof | BEIJING HOSPITAL MINISTRY HEALTH | 2013-06-26 | — | — | CN | disclosed |
| US-20130158088-A1 | TREATMENT OF HYPERTENSION AND/OR PREVENTION OR TREATMENT OF HEART FAILURE IN A MAMMAL RECEIVING ANTI-COAGULANT THERAPY | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | disclosed |
| US-8438042-B2 | Instruments and methods for obtaining informed consent to genetic tests | NATIONAL BIOMEDICAL RESEARCH FOUNDATION (US) | 2013-05-07 | — | — | US | disclosed |
| EP-1607479-B1 | SYSTEM FOR EVALUATING DRUG METABOLISM CAPACITY AND METHOD OF USING THE SAME | KANAZAWA HIDEKO (JP) | 2013-05-01 | — | — | EP | disclosed |
| CN-103079554-A | Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy | NOVARTIS AG | 2013-05-01 | — | — | CN | disclosed |
| CN-103045615-A | CYP2C9 gene segment comprising 146A>G, coded protein segment and application thereof | HU GUOXIN | 2013-04-17 | — | — | CN | disclosed |
| CN-103045619-A | CYP2C9 gene segment comprising 293G>T, coded protein segment and application thereof | CAI JIANPING | 2013-04-17 | — | — | CN | disclosed |
| CN-103045618-A | CYP2C9 gene segment comprising 394C>T, coded protein segment and application thereof | CAI JIANPING | 2013-04-17 | — | — | CN | disclosed |
| CN-103045616-A | CYP2C9 gene segment comprising 620T>C, coded protein segment and application thereof | CAI JIANPING | 2013-04-17 | — | — | CN | disclosed |
| CN-103045617-A | CYP2C9 gene segment comprising 1081C>A, coded protein segment and application thereof | CAI JIANPING | 2013-04-17 | — | — | CN | disclosed |
| CN-103031313-A | CYP2C9 gene segment comprising 370C>T, coded protein segment and application thereof | CAI JIANPING | 2013-04-10 | — | — | CN | disclosed |
| CN-103031318-A | CYP2C9 gene segment comprising 445G>A, coded protein segment and application thereof | HU GUOXIN | 2013-04-10 | — | — | CN | disclosed |
| CN-103031320-A | CYP2C9 gene segment comprising 329T>C, coded protein segment and application thereof | CAI JIANPING | 2013-04-10 | — | — | CN | disclosed |
| CN-103031321-A | CYP2C9 gene segment comprising 896C>G, coded protein segment and application thereof | CAI JIANPING | 2013-04-10 | — | — | CN | disclosed |
| CN-103031316-A | CYP2C9 gene segment comprising 1029C>A, coded protein segment and application thereof | CAI JIANPING | 2013-04-10 | — | — | CN | disclosed |
| CN-103031314-A | CYP2C9 gene segment comprising 389C>T, coded protein segment and application thereof | CAI JIANPING | 2013-04-10 | — | — | CN | disclosed |
| CN-103031317-A | CYP2C9 gene segment comprising 287G>C, coded protein segment and application thereof | CAI JIANPING | 2013-04-10 | — | — | CN | disclosed |
| CN-103031312-A | CYP2C9 gene segment comprising 448C>T, coded protein segment and application thereof | CAI JIANPING | 2013-04-10 | — | — | CN | disclosed |
| CN-103031311-A | CYP2C9 gene segment comprising 679C>T, coded protein segment and application thereof | CAI JIANPING | 2013-04-10 | — | — | CN | disclosed |
| CN-103031315-A | CYP2C9 gene segment comprising 1A>G, coded protein segment and application thereof | CAI JIANPING | 2013-04-10 | — | — | CN | disclosed |
| CN-103031319-A | CYP2C9 gene segment comprising 371G>A, coded protein segment and application thereof | CAI JIANPING | 2013-04-10 | — | — | CN | disclosed |
| US-8380539-B2 | Personalized medicine management software | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120309652-A1 | Restricted Access Media and Methods for Making Restricted Access Media | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2012-12-06 | — | — | US | disclosed |
| US-8315815-B2 | Computational methods and systems for suggesting modulators of CYP450 as treatment options | THE INVENTION SCIENCE FUND I, LLC (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| CN-102676666-A | Kit and method for detecting gene polymorphism related to warfarin personalized medication by pyro sequencing method | HONGHAO ZHOU | 2012-09-19 | — | — | CN | disclosed |
| US-8268570-B2 | Restricted access media and methods for making restricted access media | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120226054-A1 | MULTIPLE STATIONARY PHASE MATRIX AND USES THEREOF | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2012-09-06 | — | — | US | disclosed |
| CN-101760528-B | Medicine metabolic relevant loci detection method | SHANGHAI GENECORE BIO TECHNOLOGIES CO LTD | 2012-09-05 | — | — | CN | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| WO-2012092379-A2 | CELLS HAVING DISRUPTED EXPRESSION OF PROTEINS INVOLVED IN ADME AND TOXICOLOGY PROCESSES | SIGMA-ALDRICH CO. LLC (US) | 2012-07-05 | — | — | WO | disclosed |
| US-20120116795-A1 | METHOD FOR PROVIDING CURRENT ASSESSMENTS OF GENETIC RISK | NATIONAL BIOMEDICAL RESEARCH FOUNDATION | 2012-05-10 | — | — | US | disclosed |
| US-20120115802-A1 | Method for using ulipristal acetate with cytochrome isozyme modulators | LABORATOIRE HRA PHARMA (FR) | 2012-05-10 | — | — | US | disclosed |
| US-20120108623-A1 | BELOXEPIN AND ANALOGS FOR THE TREATMENT OF PAIN | ADOLOR CORPORATION (US) | 2012-05-03 | — | — | US | disclosed |
| US-8168664-B2 | Metaxalone products, method of manufacture, and method of use | MUTUAL PHARMACEUTICAL COMPANY, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| WO-2012027237-A1 | TREATMENT OF HYPERTENSION AND/OR PREVENTION OR TREATMENT OF HEART FAILURE IN A MAMMAL RECEIVING ANTI-COAGULANT THERAPY | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | disclosed |
| US-20120046876-A1 | Computational methods and systems for suggesting modulators of CYP450 as treatment options | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2012-02-23 | — | — | US | disclosed |
| WO-2011158178-A1 | USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE TREATMENT OF PATIENTS | SANOFI (FR) | 2011-12-22 | — | — | WO | disclosed |
| CN-102281758-A | Mouse having human hepatocytes transplanted therein | — | 2011-12-14 | — | — | CN | disclosed |
| US-8073633-B2 | Computational methods and systems for suggesting modulators of CYP450 as treatment options | THE INVENTION SCIENCE FUND I, LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110294820-A1 | N-Oxides of n-Phenyl-2-pyrimidine-amine Derivatives | BOERNSEN KLAUS OLAF (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110257129-A1 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20110236885-A1 | Genetic Variants Predicting Warfarin Sensitivity | ACADEMIA SINICA (TW) | 2011-09-29 | — | — | US | disclosed |
| CN-101142322-B | Gene variants for predicting warfarin sensitivity | ACADEMIA SINICA | 2011-09-21 | — | — | CN | disclosed |
| US-20110195940-A1 | Protease Inhibitors Having Enhanced Features | NEKTAR THERAPEUTICS (CA) | 2011-08-11 | — | — | US | disclosed |
| US-20110189675-A1 | Method For Administering Anticoagulation Therapy | MARSHFIELD CLINIC (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110160186-A1 | Methods of Treating CYP2D6 Alternative Metabolizers | NEKTAR THERAPEUTICS (US) | 2011-06-30 | — | — | US | disclosed |
| US-7960428-B2 | (2-carbamoyl-5-chloro-1H-indol-3-yl)-[3-((E)-2-cyano-vinyl)-5-methyl-phenyl]-(S)-phosphinic acid methyl ester; Flaviviruses; bioavailability; pharmacokinetics | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110105552-A1 | BELOXEPIN AND ANALOGS FOR THE TREATMENT OF PAIN | ADOLOR CORPORATION (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110097713-A1 | Compositions and methods for pharmacogenomic screening of CYP2C9 and VKORC1 | CATALYST ASSETS LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110065721-A1 | METAXALONE PRODUCTS, METHOD OF MANUFACTURE, AND METHOD OF USE | MUTUAL PHARMACEUTICAL COMPANY, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| CN-101928759-A | Inspection of curative effect of Warfarin anticoagulant medicament | SHANGHAI ZHUJIAN BIOENGINEERING CO LTD | 2010-12-29 | — | — | CN | disclosed |
| US-7829576-B2 | Beloxepin and analogs for the treatment of pain | ADOLOR CORPORATION (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2246445-A1 | Genetic variants of VKORC1 predicting warfarin sensitivity | Academia Sinica (TW) | 2010-11-03 | — | — | EP | disclosed |
| US-20100273203-A1 | METHODS AND COMPOSITIONS FOR DETECTING METABOLITES | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2010-10-28 | — | — | US | disclosed |
| EP-2233580-A1 | Rapid genotyping of SNPs | The Ohio State University (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100227776-A1 | Rapid Genotyping of SNPs | THE OHIO STATE UNIVERSITY (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100222362-A1 | N-OXIDES OF N-PHENYL-2-PYRAMIDINE-AMINE DERIVATIVES | BOERNSEN KLAUS OLAF | 2010-09-02 | — | — | US | disclosed |
| US-20100197797-A1 | METHODS OF MANAGING FIBROMYALGIA USING MILNACIPRAN | RAO SRINIVAS G | 2010-08-05 | — | — | US | disclosed |
| US-20100173927-A1 | administering 2,3,4,4a,13b-hexahydro-2,10-dimethyldiben-[2,3:6,7]oxepino[4,5c]pyridine-4a-ol] for treating pain associated with surgery, inflammation, cancer and neuropathic pain; pain management | ADOLOR CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100169023-A1 | Computational methods and systems for suggesting modulators of CYP450 as treatment options | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF STATE OF DELAWARE | 2010-07-01 | — | — | US | disclosed |
| CN-101760528-A | Medicine metabolic relevant loci detection method | SHANGHAI GENECORE BIO TECHNOLO | 2010-06-30 | — | — | CN | disclosed |
| US-20100160444-A1 | METHOD TO INHIBIT ISCHEMIA AND REPERFUSION INJURY | RADICAL THERAPEUTIX (US) | 2010-06-24 | — | — | US | disclosed |
| EP-2198052-A1 | METHOD FOR ADMINISTERING ANTICOAGULATION THERAPY | Marshfield Clinic (US) | 2010-06-23 | — | — | EP | disclosed |
| EP-1831402-B1 | GENETIC VARIANTS OF VKORC1 PREDICTING WARFARIN SENSITIVITY | ACADEMIA SINICA (TW) | 2010-06-09 | — | — | EP | disclosed |
| US-7682800-B2 | Agents that bind to and inhibit human cytochrome P450 2C19 | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-03-23 | — | — | US | disclosed |
| US-20100055667-A1 | Restricted Access Media and Methods for Making Restricted Access Media | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100047800-A1 | Reagents and Methods for Detecting CYP2C9 Polymorphisms | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2010-02-25 | — | — | US | disclosed |
| EP-1805323-B1 | SYSTEMS AND METHODS FOR EVALUATING ENZYME COMPETENCY | UNIV FLORIDA (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2010010343-A1 | STABILISATION | DE MONTFORT UNIVERSITY (GB) | 2010-01-28 | — | — | WO | disclosed |
| CN-101627044-A | Phosphoindoles as the enantiomer-pure of hiv inhibitor | IDENIX PHARMACEUTICALS INC | 2010-01-13 | — | — | CN | disclosed |
| US-20090318561-A1 | COLCHICINE PRODUCTS, METHOD OF MANUFACTURE, AND METHODS OF USE | MUTUAL PHARMACEUTICAL COMPANY, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009151590-A2 | METHODS OF TREATING CYP2D6 ALTERNATIVE METABOLIZERS | NEKTAR THERAPEUTICS (US) | 2009-12-17 | — | — | WO | disclosed |
| US-7632656-B2 | High performance liquid chromatography with an aqueous mobile phase for analysis of drug and its metabolite | CELLSEED INC. (JP) | 2009-12-15 | — | — | US | disclosed |
| US-7629140-B2 | Assay for cytochrome P450 isoform 2C9 | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-12-08 | — | — | US | disclosed |
| US-7615548-B2 | Method to inhibit ischemia and reperfusion injury | RADICAL THERAPEUTIX (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090239879-A1 | N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | BORNSEN KLAUS OLAF | 2009-09-24 | — | — | US | disclosed |
| US-20090233957-A1 | (-)-BELOXEPIN AND METHODS FOR ITS SYNTHESIS AND USE | ADOLOR CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090233959-A1 | BELOXEPIN AND ANALOGS FOR THE TREATMENT OF PAIN | ADOLOR CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090233958-A1 | (+)-BELOXEPIN AND METHODS FOR ITS SYNTHESIS AND USE | ADOLOR CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090226909-A1 | Methods and kits for Determining Predisposition to Warfarin Resistance | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2009-09-10 | — | — | US | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-2078029-A2 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| US-7557105-B2 | Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | NOVARTIS AG (CH) | 2009-07-07 | — | — | US | disclosed |
| US-20090138286-A1 | PERSONALIZED MEDICINE MANAGEMENT SOFTWARE | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC, | 2009-05-28 | — | — | US | disclosed |
| CN-101422442-A | Levetiracetam osmotic pump controlled release tablet and preparation method thereof | UNIV SHENYANG PHARMACEUTICAL (CN) | 2009-05-06 | — | — | CN | disclosed |
| US-7524939-B2 | Antibodies that bind to and inhibit human cytochrome P450 2C9*1, 2C9*2, and 2C9*3 | UNITED STATES OF AMERICA AS REPRESENTED BY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-04-28 | — | — | US | disclosed |
| WO-2009052160-A1 | METHOD FOR ADMINISTERING ANTICOAGULATION THERAPY | MARSHFIELD CLINIC (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090087856-A1 | METHOD FOR ADMINISTERING ANTICOAGULATION THERAPY | MARSHFIELD CLINIC (US) | 2009-04-02 | — | — | US | disclosed |
| EP-2011489-A2 | Method to inhibit ischemia and reperfusion injury | Gottlieb, Roberta (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20090005270-A1 | Systems and Methods for Evaluating Enzyme Competency | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| EP-2004858-A2 | METHODS AND KITS FOR DETERMINING PREDISPOSITION TO WARFARIN RESISTANCE | Tel HaShomer Medical Research Infrastructure and Services Ltd. (IL) | 2008-12-24 | — | — | EP | disclosed |
| US-20080292584-A1 | METAXALONE PRODUCTS, METHOD OF MANUFACTURE, AND METHOD OF USE | MUTUAL PHARMACEUTICAL COMPANY, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| US-20080213217-A1 | Enantiomerically pure phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| WO-2008106437-A1 | COMPOSITIONS AND METHODS FOR PHARMACOGENOMIC SCREENING OF CYP2C9 AND VKORC1 | PARAGONDX, LLC (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20080193950-A1 | Rapid and sensitive; radiometric; automatic; multiwell plates; incubating with tritium-labeled diclofenac | MERCK SHARP & DOHME CORP. | 2008-08-14 | — | — | US | disclosed |
| WO-2008042240-A9 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20080124416-A1 | THERAPEUTIC COMPOSITION FROM GOJI (LYCIUM BARBARUM L.), METHODS OF MAKING AND USING | RENAISSANCE HERBS, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-7378434-B2 | Metaxalone products, method of manufacture, and method of use | MUTUAL PHARMACEUTICAL COMPANY, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| CN-101171036-A | Delivery of TIGECYCLINE in the presence of WARFARIN | WYETH CORP (US) | 2008-04-30 | — | — | CN | disclosed |
| US-20080096872-A1 | Composition for Treatment of Pain Specification | FRIEDMAN ROBERT S | 2008-04-24 | — | — | US | disclosed |
| WO-2008042240-A2 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| EP-1799843-A4 | ASSAY FOR CYTOCHROME P450 ISOFORM 2C9 | MERCK & CO INC (US) | 2008-04-09 | — | — | EP | disclosed |
| CN-101142322-A | Gene variants for predicting warfarin sensitivity | ACADEMIA SINICA (CN) | 2008-03-12 | — | — | CN | disclosed |
| US-20080045564-A1 | QUININE PRODUCTS, METHOD OF MANUFACTURE, METHOD OF USE | MUTUAL PHARMACEUTICAL COMPANY, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080039492-A1 | Quinine products, method of manufacture, and method of use | MUTUAL PHARMACEUTICAL COMPANY, INC., A PENNSYLVANIA CORPORATION | 2008-02-14 | — | — | US | disclosed |
| EP-1877092-A2 | DELIVERY OF TIGECYCLINE IN THE PRESENCE OF WARFARIN | Wyeth (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007133506-A2 | PERSONALIZED MEDICINE MANAGEMENT SOFTWARE | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION , INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| EP-1603548-A4 | METHOD AND COMPOSITION FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS INC (US) | 2007-10-10 | — | — | EP | disclosed |
| WO-2007110869-A2 | METHODS AND KITS FOR DETERMINING PREDISPOSITION TO WARFARIN RESISTANCE | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2007-10-04 | — | — | WO | disclosed |
| US-7262018-B2 | Agents that bind to and inhibit human cytochrome P450 2C19 | NATIONAL INSTITUTES OF HEALTH (US) | 2007-08-28 | — | — | US | disclosed |
| WO-2007094825-A2 | METAXALONE PRODUCTS, METHOD OF MANUFACTURE, AND METHOD OF USE | MUTUAL PHARMACEUTICAL COMPANY, INC. (US) | 2007-08-23 | — | — | WO | disclosed |
| US-20070179716-A1 | Crystal structure of cytochrome P450 3A4 and uses thereof | ASTEX THERAPEUTICS LIMITED (GB) | 2007-08-02 | — | — | US | disclosed |
| US-20070166816-A1 | Assay device that analyzes the absorption, metabolism, permeability and/or toxicity of a candidate compound | SURFACE LOGIX, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| EP-1805323-A2 | SYSTEMS AND METHODS FOR EVALUATING ENZYME COMPETENCY | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070154971-A1 | AGENTS THAT BIND TO AND INHIBIT HUMAN CYTOCHROME P450 2C19 | NATIONAL INSTITUTES OF HEALTH (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1799843-A2 | ASSAY FOR CYTOCHROME P450 ISOFORM 2C9 | Merck & Co., Inc. (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1783126-A2 | N-oxides of N-phenyl-2-pyrimidine-amine derivatives | Novartis AG (CH) | 2007-05-09 | — | — | EP | disclosed |
| US-20070088065-A1 | Metaxalone products, method of manufacture, and method of use | MUTUAL PHARMACEUTICAL COMPANY, INC., A PENNSYLVANIA CORPORATION | 2007-04-19 | — | — | US | disclosed |
| US-20070088066-A1 | Metaxalone products, method of manufacture, and method of use | MPC OLDCO, INC. | 2007-04-19 | — | — | US | disclosed |
| EP-1476578-A4 | MISMATCH REPAIR DETECTION | UNIV CALIFORNIA (US) | 2007-03-14 | — | — | EP | disclosed |
| CN-1928083-A | Single nucleotide polymorphism of human heterogenous substance metabolizing enzyme gene and application thereof in diagnosis and treatment of colorectal cancer | HUAJING GENE TECHNOLOGY CO LTD (HK) | 2007-03-14 | — | — | CN | disclosed |
| CN-1296708-C | Double column switching chromatograph preparing device for chira medicine saparation | DALIAN CHEMICAL PHYSICS INST (CN) | 2007-01-24 | — | — | CN | disclosed |
| EP-1740613-A2 | CRYSTAL STRUCTURE OF CYTOCHROME P450 3A4 AND USES THEREOF | Astex Therapeutics Limited (GB) | 2007-01-10 | — | — | EP | disclosed |
| US-7153652-B2 | Mismatch repair detection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060270638-A1 | Delivery of tigecycline in the presence of warfarin | WYETH (US) | 2006-11-30 | — | — | US | disclosed |
| US-7138499-B2 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | APPLERA CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| WO-2006121666-A2 | DELIVERY OF TIGECYCLINE IN THE PRESENCE OF WARFARIN | WYETH (US) | 2006-11-16 | — | — | WO | disclosed |
| US-7122566-B1 | Metaxalone products, method of manufacture, and method of use | MUTUAL PHARMACEUTICAL COMPANY, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20060228770-A1 | Evaluation system for drug-metabolizing capacity and use thereof | CELLSEED INC. (JP) | 2006-10-12 | — | — | US | disclosed |
| US-20060166239-A1 | Genetic variants predicting warfarin sensitivity | ACADEMIA SINICA (TW) | 2006-07-27 | — | — | US | disclosed |
| US-20060116826-A1 | Crystals of cytochrome P450 2C9, structures thereof and their use | ASTEX THERAPEUTICS LIMITED (GB) | 2006-06-01 | — | — | US | disclosed |
| WO-2006041844-A2 | ASSAY FOR CYTOCHROME P450 ISOFORM 2C9 | MERCK & CO., INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006034370-A2 | SYSTEMS AND METHODS FOR EVALUATING ENZYME COMPETENCY | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060062859-A1 | Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes | KENBER RESEARCH, LLC | 2006-03-23 | — | — | US | disclosed |
| EP-1632577-A2 | Apparatus, method, and computer product for supporting estimation of metabolism | FUJITSU LIMITED (JP) | 2006-03-08 | — | — | EP | disclosed |
| US-20060047440-A1 | Apparatus, method, and computer product for supporting estimation of metabolism | FUJITSU LIMITED (JP) | 2006-03-02 | — | — | US | disclosed |
| EP-1623024-A2 | CRYSTALS OF CYTOCHROME P450 2C9, STRUCTURES THEREOF AND THEIR USE | Astex Therapeutics Limited (GB) | 2006-02-08 | — | — | EP | disclosed |
| US-6987014-B2 | Isolated nucleic acid molecules encoding human drug metabolizing proteins | APPLERA CORPORATION (US) | 2006-01-17 | — | — | US | disclosed |
| WO-2006002127-A1 | TRANSDERMAL DELIVERY SYSTEM FOR STATIN COMBINATION THERAPY | FAIRFIELD CLINICAL TRIALS, LLC (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288375-A1 | Method and composition for treating neurodegenerative disorders | MYRIAD GENETICS, INCORPORATED (US) | 2005-12-29 | — | — | US | disclosed |
| US-20050281868-A1 | Transdermal delivery system for statin combination therapy | FAIRFIELD CLINICAL TRIALS, LLC (US) | 2005-12-22 | — | — | US | disclosed |
| EP-1607479-A1 | SYSTEM FOR EVALUATING DRUG METABOLISM CAPACITY AND METHOD OF USING THE SAME | Kanazawa, Hideko (JP) | 2005-12-21 | — | — | EP | disclosed |
| EP-1603548-A2 | METHOD AND COMPOSITION FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-6967094-B2 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | APPLERA CORPORATION (US) | 2005-11-22 | — | — | US | disclosed |
| WO-2005105842-A2 | CRYSTAL STRUCTURE OF CYTOCHROME P450 3A4 AND USES THEREOF | ASTEX THERAPEUTICS LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
| US-6953681-B2 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | APPLERA CORPORATION (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050215533-A1 | Method to inhibit ischemia and reperfusion injury | RADICAL THERAPEUTIX | 2005-09-29 | — | — | US | disclosed |
| US-6949371-B2 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | APPLERA CORPORATION (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050208484-A1 | ISOLATED NUCLEIC ACID MOLECULES ENCODING HUMAN DRUGMETOBOLIZING PROTEINS | APPLIED BIOSYSTEMS, LLC | 2005-09-22 | — | — | US | disclosed |
| US-20050209452-A1 | Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | NOVARTIS AG (CH) | 2005-09-22 | — | — | US | disclosed |
| US-20050196802-A1 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | APPLERA CORPORATION (US) | 2005-09-08 | — | — | US | disclosed |
| EP-1383788-A4 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF | APPLERA CORP (US) | 2005-08-31 | — | — | EP | disclosed |
| EP-1385978-A4 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING THESE HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF | APPLERA CORP (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050170419-A1 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | APPLERA CORPORATION (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050153345-A1 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | APPLERA CORPORATION (US) | 2005-07-14 | — | — | US | disclosed |
| US-20050148013-A1 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | APPLERA CORPORATION (US) | 2005-07-07 | — | — | US | disclosed |
| US-6908738-B2 | Agents that bind to and inhibit human cytochrome P450 2C19 | NATIONAL INSTITUTE OF HEALTH (US) | 2005-06-21 | — | — | US | disclosed |
| US-6905855-B2 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | APPLERA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1379629-A4 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF | APPLERA CORP (US) | 2005-05-18 | — | — | EP | disclosed |
| EP-1523310-A2 | METHOD TO INHIBIT ISCHEMIA AND REPERFUSION INJURY | The Scripps Research Institute (US) | 2005-04-20 | — | — | EP | disclosed |
| US-20050075487-A1 | Agents that bind to and inhibit human cytochrome P450 2C8, 2C9, 2C18 and 2C19 | HEALTH AND HUMAN SERVICES, DEPARTMENT OF UNITED STATES OF AMERICA (US) | 2005-04-07 | — | — | US | disclosed |
| US-6875597-B2 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | APPLERA CORPORATION (US) | 2005-04-05 | — | — | US | disclosed |
| US-20050054009-A1 | Agents that bind to and inhibit human cytochrome P450 2C19 | NATIONAL INSTITUTES OF HEALTH (US) | 2005-03-10 | — | — | US | disclosed |
| US-20050032119-A1 | Crystal structure of cytochrome P450 | ASTEX TECHNOLOGY LTD. (GB) | 2005-02-10 | — | — | US | disclosed |
| US-20050033056-A1 | Hydroxylated indole derivatives and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-02-10 | — | — | US | disclosed |
| US-6846661-B2 | Isolated human UDP-glycosyltransferase, nucleic acid molecules encoding human UDP-glycosyltransferase, and uses thereof | APPLERA CORPORATION (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040241794-A1 | Isolated human drug-metabolizing proteins , nucleic acid molecules encoding these drug- metabolizing proteins, and uses thereof | APPLIED BIOSYSTEMS, LLC | 2004-12-02 | — | — | US | disclosed |
| US-20040241714-A1 | Methods of assessment of drug metabolizing enzymes | UNIVERSITY OF PITTSBURGH | 2004-12-02 | — | — | US | disclosed |
| EP-1476578-A2 | MISMATCH REPAIR DETECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-11-17 | — | — | EP | disclosed |
| WO-2004096857-A2 | CRYSTALS OF CYTOCHROME P450 2C9, STRUCTURES THEREOF AND THEIR USE | ASTEX THERAPEUTICS LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004071431-A2 | METHOD AND COMPOSITION FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| EP-1448766-A2 | COISOGENIC EUKARYOTIC CELL COLLECTIONS | UNIVERSITY OF DELAWARE (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20040152163-A1 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | APPLERA CORPORATION | 2004-08-05 | — | — | US | disclosed |
| US-20040132089-A1 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | APPLERA CORPORATION | 2004-07-08 | — | — | US | disclosed |
| US-20040101477-A1 | Individualization of therapy with anesthetics | XANTHUS LIFE SCIENCES, INC. | 2004-05-27 | — | — | US | disclosed |
| WO-2002084288-A9 | INDIVIDUALIZATION OF THERAPY WITH ANTIARRHYTHMICS | UNIV MCGILL (CA) | 2004-05-27 | — | — | WO | disclosed |
| US-20040091909-A1 | High throughput cytochrome P450 genotyping | HUANG DOUG HUI (US) | 2004-05-13 | — | — | US | disclosed |
| EP-0914446-B1 | CYTOCHROME P450 EXPRESSION IN ENTEROBACTERIA | BTG INT LTD (GB) | 2004-05-12 | — | — | EP | disclosed |
| US-20040084867-A1 | Individualization of therapy with anticoagulants | XANTHUS LIFE SCIENCES, INC. | 2004-05-06 | — | — | US | disclosed |
| US-6730505-B2 | AMINO ACID SEQUENCES OF PEPTIDES THAT ARE ENCODED BY GENES WITHIN THE HUMAN GENOME, THE DRUG-METABOLIZING ENZYME PEPTIDES OF THE PRESENT INVENTION. THE PRESENT INVENTION SPECIFICALLY PROVIDES ISOLATED PEPTIDE AND NUCLEIC ACID MOLECULES, METHODS | APPLERA CORPORATION | 2004-05-04 | — | — | US | disclosed |
| US-6727104-B2 | DETERMINE THE CONCENTRATION OF PREFERENTIAL ANALYTE IN SAMPLE; OBTAIN SAMPLE, APPLY TO IMMUNOAFFINITY COLUMN, SEPARATE PARTICLES, DETERMINE PREEFRENTIAL PARTICLE CONCENTRATION BY CHROMATOGRAPHIC IMMUNOASSAY | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2004-04-27 | — | — | US | disclosed |
| US-6720193-B2 | DETERMINING CONCENTRATION OF PREFERENTIAL PARTICLES IN SAMPLE; OBTAIN SAMPLE, APPLY TO COLUMN, MONITOR COLUMN FOR SIGNAL, DETERMINE CONCENTRATION PREFERENTIAL PARTICLE IN SAMPLE | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2004-04-13 | — | — | US | disclosed |
| US-6713295-B2 | PEPTIDE FOR USE IN THE TREATMENT OF CANCER, PARKINSON'S AND DEVELOPMENTAL DEFECTS | APPLERA CORPORATION | 2004-03-30 | — | — | US | disclosed |
| US-20040053383-A1 | Crystals of cytochrome P450 2C9, structures thereof and their use | ASTEX TECHNOLOGY LTD. (GB) | 2004-03-18 | — | — | US | disclosed |
| WO-2002064816-A9 | MULTIPLE DETERMINANTS FOR METABOLIC PHENOTYPES | UNIV MCGILL (CA) | 2004-03-18 | — | — | WO | disclosed |
| US-20040043413-A1 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | APPLERA CORPORATION (US) | 2004-03-04 | — | — | US | disclosed |
| US-20040023230-A1 | Method and nucleic acids for pharmacogenomic methylation analysis | EPIGENOMICS AG (DE) | 2004-02-05 | — | — | US | disclosed |
| EP-1385978-A2 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING THESE HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF | PE Corporation (NY) (US) | 2004-02-04 | — | — | EP | disclosed |
| EP-1386156-A2 | INDIVIDUALIZATION OF THERAPY WITH ANTINEOPLASTIC AGENTS | McGILL UNIVERSITY (CA) | 2004-02-04 | — | — | EP | disclosed |
| EP-1383788-A1 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF | PE Corporation (NY) (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2004004702-A2 | METHOD TO INHIBIT ISCHEMIA AND REPERFUSION INJURY | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-01-15 | — | — | WO | disclosed |
| EP-1379872-A2 | USE OF METABOLIC PHENOTYPING IN INDIVIDUALIZED TREATMENT WITH AMONAFIDE | McGILL UNIVERSITY (CA) | 2004-01-14 | — | — | EP | disclosed |
| EP-1379629-A1 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF | PE Corporation (NY) (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2004003550-A2 | INDIVIDUALIZATION OF THERAPY WITH ANTICOAGULANTS | XANTHUS LIFE SCIENCES, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| EP-1373551-A2 | MULTIPLE DETERMINANTS FOR METABOLIC PHENOTYPES | McGill University (CA) | 2004-01-02 | — | — | EP | disclosed |
| EP-1370865-A2 | METABOLIC PHENOTYPING IN THERAPY WITH IMMUNOSUPPRESSANTS | McGILL UNIVERSITY (CA) | 2003-12-17 | — | — | EP | disclosed |
| EP-1366186-A2 | DETECTION OF CYP3A4 AND CYP2C9 POLYMORPHISMS | Sequenom-Gemini Limited (GB) | 2003-12-03 | — | — | EP | disclosed |
| US-20030215915-A1 | Cytochrome P450 expression in enterobacteria | BTG INTERNATIONAL LIMITED (GB) | 2003-11-20 | — | — | US | disclosed |
| US-20030207327-A1 | Coisogenic eukaryotic cell collections | DELAWARE, UNIVERSITY OF | 2003-11-06 | — | — | US | disclosed |
| EP-1358334-A2 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF | PE Corporation (NY) (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030195350-A1 | Individualization of therapy with antiviral agents | XANTHUS LIFE SCIENCES, INC | 2003-10-16 | — | — | US | disclosed |
| US-20030190671-A1 | Use of metabolic phenotyping in individualized treatment with amonafide | MCGILL UNIVERSITY (CA) | 2003-10-09 | — | — | US | disclosed |
| US-20030185753-A1 | ELISA kit for the determination of CYP 2C9 metabolic phenotypes and uses therefor | XANTHUS LIFE SCIENCES, INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030186339-A1 | Individualization of therapy with antibiotic agents | MCGILL UNIVERSITY | 2003-10-02 | — | — | US | disclosed |
| US-20030180823-A1 | Individualization of therapy with antihistamines | XANTHUS LIFE SCIENCES, INC. | 2003-09-25 | — | — | US | disclosed |
| EP-1346051-A2 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF | PE Corporation (NY) (US) | 2003-09-24 | — | — | EP | disclosed |
| US-6623960-B1 | Agents that bind to and inhibit human cytochrome P450 2C8, 2C9, 2C18 and 2C19 | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-09-23 | — | — | US | disclosed |
| US-20030175210-A1 | Study drug metabolic reactions of each indivial, detecting metabolites in a biological sample after administering the drug | MCGILL UNIVERSITY (CA) | 2003-09-18 | — | — | US | disclosed |
| US-20030170176-A1 | Individualization of therapy with antipsychotics | MCGILL UNIVERSITY (CA) | 2003-09-11 | — | — | US | disclosed |
| US-20030166189-A1 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | PE CORPORATION (NY) | 2003-09-04 | — | — | US | disclosed |
| US-20030166187-A1 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | PE CORPORATION (NY) | 2003-09-04 | — | — | US | disclosed |
| US-20030166182-A1 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | APPLIED BIOSYSTEMS, LLC | 2003-09-04 | — | — | US | disclosed |
| EP-1339836-A2 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF | PE Corporation (NY) (US) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003070974-A2 | MISMATCH REPAIR DETECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003067257-A1 | INDIVIDUALIZATION OF THERAPY WITH ANXIOLITICS | MCGILL UNIVERSITY (CA) | 2003-08-14 | — | — | WO | disclosed |
| WO-2003059351-A1 | HYDROXYLATED INDOLE DERIVATIVES AND USES THEREOF | EISAI CO., LTD. (JP) | 2003-07-24 | — | — | WO | disclosed |
| US-20030138375-A1 | Individualization of therapy with Alzheimer's disease agents | MCGILL UNIVERSITY (CA) | 2003-07-24 | — | — | US | disclosed |
| US-20030138377-A1 | Use of metabolic phenotyping in individualized treatment with amonafide | MCGILL UNIVERISTY (CA) | 2003-07-24 | — | — | US | disclosed |
| US-20030124636-A1 | Individualization of therapy with antiarrhythmics | MCGILL UNIVERSITY (CA) | 2003-07-03 | — | — | US | disclosed |
| WO-2003052123-A1 | INDIVIDUALIZATION OF THERAPY WITH ANTIHISTAMINES | XANTHUS LIFE SCIENCES, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003052425-A2 | ELISA KIT FOR CYP 2C9 METABOLIC PHENOTYPES | XANTHUS LIFE SCIENCES, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| US-20030108484-A1 | Individualization of therapy with antineoplastic agents | MCGILL UNIVERSITY | 2003-06-12 | — | — | US | disclosed |
| WO-2003046559-A2 | INDIVIDUALIZATION OF THERAPY WITH ANTIVIRAL AGENTS | XANTHUS LIFE SCIENCES, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003046583-A2 | INDIVIDUALIZATION OF THERAPY WITH ANESTHETICS | XANTHUS LIFE SCIENCES INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20030104592-A1 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | APPLERA CORPORATION | 2003-06-05 | — | — | US | disclosed |
| EP-1313840-A2 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES AND USES THEREOF | Applera Corporation (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002084288-A3 | INDIVIDUALIZATION OF THERAPY WITH ANTIARRHYTHMICS | UNIV MCGILL (CA) | 2003-05-22 | — | — | WO | disclosed |
| US-6566108-B1 | Genetically engineered cell for use in the expression of heterologous proteins and particles | UNIVERSITY OF DUNDEE (GB) | 2003-05-20 | — | — | US | disclosed |
| US-20030091975-A1 | Multiple determinants for metabolic phenotypes | MCGILL UNIVERSITY (CA) | 2003-05-15 | — | — | US | disclosed |
| US-20030077222-A1 | Individualization of therapy with analgesics | MCGILL UNIVERSITY (CA) | 2003-04-24 | — | — | US | disclosed |
| US-20030073133-A1 | Individualization of therapy with erectile dysfunction agents | MCGILL UNIVERSITY (CA) | 2003-04-17 | — | — | US | disclosed |
| US-20030072710-A1 | Individualization of therapy with antidepressants | MCGILL UNIVERSITY (CA) | 2003-04-17 | — | — | US | disclosed |
| US-20030068273-A1 | Individualization of therapy with immunosuppressants | MCGILL UNIVERSITY (CA) | 2003-04-10 | — | — | US | disclosed |
| WO-2003027264-A2 | COISOGENIC EUKARYOTIC CELL COLLECTIONS | UNIVERSITY OF DELAWARE (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-1294947-A2 | METHOD AND NUCLEIC ACIDS FOR PHARMACOGENOMIC METHYLATION ANALYSIS | Epigenomics AG (DE) | 2003-03-26 | — | — | EP | disclosed |
| US-20030053950-A1 | Individualization of therapy with hyperlipidemia agents | MCGILL UNIVERSITY (CA) | 2003-03-20 | — | — | US | disclosed |
| US-20030049204-A1 | Individualization of therapy with gastroesophageal reflux disease agents | MCGILL UNIVERSITY (CA) | 2003-03-13 | — | — | US | disclosed |
| US-6531297-B2 | Peptide; for use as tools in human therapeutics and diagnostics | APPLERA CORPORATION | 2003-03-11 | — | — | US | disclosed |
| WO-2003008637-A2 | USE OF GENOTYPING IN THE INDIVIDUALIZATION OF THERAPY | XANTHUS LIFE SCIENCES, INC. (US) | 2003-01-30 | — | — | WO | disclosed |
| EP-1278827-A2 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF | PE Corporation (NY) (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20030017469-A1 | Detection of CYP3A4 and CYP2C9 polymorphisms | SEQUENOM-GEMINI LIMITED (GB) | 2003-01-23 | — | — | US | disclosed |
| CN-1392413-A | Double column switching chromatograph preparing device for chira medicine saparation | DALIAN CHEMICAL PHYSICS INST (CN) | 2003-01-22 | — | — | CN | disclosed |
| US-20030008354-A1 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | PE CORPORATION (NY) (US) | 2003-01-09 | — | — | US | disclosed |
| US-20030003472-A1 | Mismatch repair detection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-02 | — | — | US | disclosed |
| WO-2001072977-A9 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF | PE CORP NY (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002099422-A2 | INDIVIDUALIZATION OF THERAPY WITH ALZHEIMER'S DISEASE AGENTS | MCGILL UNIVERSITY (CA) | 2002-12-12 | — | — | WO | disclosed |
| US-20020182681-A1 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | PE CORPORATION (NY) (US) | 2002-12-05 | — | — | US | disclosed |
| US-20020182692-A1 | ISOLATED HUMAN UDP-GLYCOSYLTRANSFERASE PROTEINS | PE CORPORATION (NY) (US) | 2002-12-05 | — | — | US | disclosed |
| WO-2002095402-A2 | INDIVIDUALIZATION OF THERAPY WITH HYPERLIPIDEMIA AGENTS | MCGILL UNIVERSITY (CA) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002093162-A2 | INDIVIDUALIZATION OF THERAPY WITH ANTIBIOTIC AGENTS | MCGILL UNIVERSITY (CA) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002090994-A2 | INDIVIDUALIZATION OF THERAPY WITH ANALGESICS | MCGILL UNIVERSITY (CA) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002088753-A1 | INDIVIDUALIZATION OF THERAPY WITH ERECTILE DYSFUNCTION AGENTS | MCGILL UNIVERSITY (CA) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002088714-A2 | INDIVIDUALIZATION OF THERAPY WITH ANTINEOPLASTIC AGENTS | MCGILL UNIVERSITY (CA) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002086504-A2 | INDIVIDUALIZATION OF THERAPY WITH GASTROESOPHAGEAL REFLUX DISEASE AGENTS | MCGILL UNIVERSITY (CA) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002084288-A2 | INDIVIDUALIZATION OF THERAPY WITH ANTIARRHYTHMICS | MCGILL UNIVERSITY (CA) | 2002-10-24 | — | — | WO | disclosed |
| US-20020151015-A1 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | PE CORPORATION (NY) (US) | 2002-10-17 | — | — | US | disclosed |
| US-20020151087-A1 | Microcolumn chromatographic immunoassays | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-10-17 | — | — | US | disclosed |
| US-20020151086-A1 | Analysis of free analyte fractions by rapid affinity chromatography | NATIONAL INSTITUTES OF HEALTH | 2002-10-17 | — | — | US | disclosed |
| WO-2002079233-A1 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF | PE CORPORATION (NY) (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020142379-A1 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | SHAO WEI (US) | 2002-10-03 | — | — | US | disclosed |
| WO-2002077644-A1 | MICROCOLUMN CHROMATOGRAPHIC IMMUNOASSAYS | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2002-10-03 | — | — | WO | disclosed |
| WO-2002077214-A1 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF | PE CORPORATION (NY) (US) | 2002-10-03 | — | — | WO | disclosed |
| WO-2002077265-A2 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING THESE HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF | PE CORPORATION (NY) (US) | 2002-10-03 | — | — | WO | disclosed |
| WO-2002073197-A2 | INDIVIDUALIZATION OF THERAPY WITH ANTIDEPRESSANTS | MCGILL UNIVERSITY (CA) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002073196-A2 | INDIVIDUALIZATION OF THERAPY WITH ANTIPSYCHOTICS | MCGILL UNIVERSITY (CA) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002073206-A2 | METABOLIC PHENOTYPING IN THERAPY WITH ANXIOLYTICS | MCGILL UNIVERSITY (CA) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002073205-A2 | METABOLIC PHENOTYPING IN THERAPY WITH IMMUNOSUPPRESSANTS | MCGILL UNIVERSITY (CA) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002071060-A2 | USE OF METABOLIC PHENOTYPING IN INDIVIDUALIZED TREATMENT WITH AMONAFIDE | MCGILL UNIVERSITY (CA) | 2002-09-12 | — | — | WO | disclosed |
| US-20020115124-A1 | Agents that bind to and inhibit human cytochrome P450 2C19 | NATIONAL INSTITUTES OF HEALTH | 2002-08-22 | — | — | US | disclosed |
| WO-2002064816-A2 | MULTIPLE DETERMINANTS FOR METABOLIC PHENOTYPES | MCGILL UNIVERSITY (CA) | 2002-08-22 | — | — | WO | disclosed |
| US-6436684-B1 | ISOLATED NUCLEIC ACID MOLECULE CONSISTING OF SELECTED NUCLEOTIDE SEQUENCE ENCODING PHENOL SULFOTRANSFERASE PROTEIN | APPLERA CORPORATION | 2002-08-20 | — | — | US | disclosed |
| US-6420150-B1 | FOR USE IN DEVELOPMENT OF HUMAN THERAPEUTICS | PE CORPORATION (NY) | 2002-07-16 | — | — | US | disclosed |
| US-20020086381-A1 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF | APPLIED BIOSYSTEMS, LLC | 2002-07-04 | — | — | US | disclosed |
| WO-2002050283-A2 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF | PE CORPORATION (NY) (US) | 2002-06-27 | — | — | WO | disclosed |
| US-20020082194-A1 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | GUEGLER KARL (US) | 2002-06-27 | — | — | US | disclosed |
| US-20020076774-A1 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | APPLIED BIOSYSTEMS, LLC | 2002-06-20 | — | — | US | disclosed |
| US-20020076777-A1 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | APPLIED BIOSYSTEMS, LLC | 2002-06-20 | — | — | US | disclosed |
| WO-2002042437-A2 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF | PE CORPORATION (NY) (US) | 2002-05-30 | — | — | WO | disclosed |
| US-6383789-B1 | NUCLEOTIDE AND AMINO ACID SEQUENCE OF URIDINE DIPHOSPHATE-GLYCOSYLTRANSFERASE, A DRUG-METABOLIZING ENZYME; FOR RECOMBINANT CULTURE PRODUCTION OF THE ENZYME | PE CORPORATION (NY) | 2002-05-07 | — | — | US | disclosed |
| WO-2002034922-A2 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF | PE CORPORATION (NY) (US) | 2002-05-02 | — | — | WO | disclosed |
| WO-2002018641-A2 | DETECTION OF CYP3A4 AND CYP2C9 POLYMORPHISMS | SEQUENOM-GEMINI LIMITED (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002018554-A2 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULESAND USES THEREOF | APPLERA CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
| US-20020022254-A1 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | APPLIED BIOSYSTEMS INC. | 2002-02-21 | — | — | US | disclosed |
| WO-2002002806-A2 | METHOD AND NUCLEIC ACIDS FOR ANALYSING THE METHYLATION OF GENES IMPLICATED IN PHARMACOGENOMICS | EPIGENOMICS AG (DE) | 2002-01-10 | — | — | WO | disclosed |
| WO-2000047627-A9 | AGENTS THAT BIND TO AND INHIBIT HUMAN CYTOCHROME P450 2C8, 2C9, 2C18 AND 2C19 | US GOV HEALTH & HUMAN SERV (US) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001072977-A2 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF | PE CORPORATION (NY) (US) | 2001-10-04 | — | — | WO | disclosed |
| EP-0839142-B1 | A NOVEL ASYMMETRIC SYNTHESIS OF R AND S WARFARIN AND ITS ANALOGS | DU PONT PHARM CO (US) | 2001-09-12 | — | — | EP | disclosed |
| EP-1108065-A1 | A METHOD FOR MEASURING A PATIENT'S ABILITY TO METABOLISE CERTAIN DRUGS | Sangtec Molecular Diagnostics AB (SE) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000047627-A1 | AGENTS THAT BIND TO AND INHIBIT HUMAN CYTOCHROME P450 2C8, 2C9, 2C18 AND 2C19 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000043003-A1 | THE THERAPEUTIC USE OF R-WARFARIN AS ANTICOAGULANT | DARWIN DISCOVERY LIMITED (GB) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000043003-A1 | THE THERAPEUTIC USE OF R-WARFARIN AS ANTICOAGULANT | DARWIN DISCOVERY LIMITED (GB) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000012757-A1 | A METHOD FOR MEASURING A PATIENT'S ABILITY TO METABOLISE CERTAIN DRUGS | SANGTEC MOLECULAR DIAGNOSTICS AB (SE) | 2000-03-09 | — | — | WO | disclosed |
| US-5856525-A | ANTICOAGULANTS; RACEMIC MIXTURE OF S AND R-WARFARIN | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-01-05 | — | — | US | disclosed |
| EP-0839142-A1 | A NOVEL ASYMMETRIC SYNTHESIS OF R AND S WARFARIN AND ITS ANALOGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-05-06 | — | — | EP | disclosed |
| US-5686631-A | OXIDATION OF RACEMATE, STEREOSPECIFIC HYDROGENATION WITH CHIRAL PHOSPHINE CATALYST | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-11-11 | — | — | US | disclosed |
| WO-1997003062-A1 | A NOVEL ASYMMETRIC SYNTHESIS OF R AND S WARFARIN AND ITS ANALOGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-01-30 | — | — | WO | disclosed |
| WO-1997003062-A1 | A NOVEL ASYMMETRIC SYNTHESIS OF R AND S WARFARIN AND ITS ANALOGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233555-A1 | METHOD OF ADMINISTERING UPADACITINIB TO AVOID ADVERSE DRUG INTERACTIONS AND EFFECTS | CYP3A4, CYP2C8, CYP3A43 | VKORC1 41/4885CYP2C9 8/4885ALB 932/4885 |
| US-20230022446-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer | AR, KLK3, SHBG | VKORC1 3123/4885CYP2C9 1871/4885ALB 2280/4885 |
| US-20230015823-A1 | METHODS OF ADMINISTERING VOXELOTOR | CYP3A7, UGT2B7, UGT1A1 | VKORC1 102/4885CYP2C9 24/4885ALB 1166/4885 |
| US-11160796-B2 | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer | AR, KLK3, SHBG | VKORC1 3123/4885CYP2C9 1871/4885ALB 2280/4885 |
| US-11491149-B2 | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer | AR, KLK3, SHBG | VKORC1 3123/4885CYP2C9 1871/4885ALB 2280/4885 |
| US-20220160695-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | AR, KLK3, SHBG | VKORC1 1778/4885CYP2C9 2234/4885ALB 742/4885 |
| US-20100173927-A1 | administering 2,3,4,4a,13b-hexahydro-2,10-dimethyldiben-[2,3:6,7]oxepino[4,5c]pyridine-4a-ol] for treating pain associated with surgery, inflammation, cancer and neuropathic pain; pain management | OPRL1, OPRK1, OPRM1 | VKORC1 1179/4885CYP2C9 1024/4885ALB 2496/4885 |
| US-10806794-B2 | Protease inhibitors having enhanced features | SERPINB1, SPINT2, TMPRSS15 | VKORC1 274/4885CYP2C9 105/4885ALB 683/4885 |
| US-20120115802-A1 | Method for using ulipristal acetate with cytochrome isozyme modulators | CYP3A43, CYP1A2, CYP51A1 | VKORC1 68/4885CYP2C9 16/4885ALB 3087/4885 |
| US-20230277630-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | CYP27A1, SLC10A1, CYP7A1 | VKORC1 1186/4885CYP2C9 82/4885ALB 2291/4885 |
| US-10092656-B2 | Protease inhibitors having enhanced features | SERPINB1, SPINT2, TMPRSS15 | VKORC1 274/4885CYP2C9 105/4885ALB 683/4885 |
| US-20240299409-A1 | TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS | ROCK2, ROCK1, CIT | VKORC1 1364/4885CYP2C9 4852/4885ALB 4424/4885 |
| US-20090233959-A1 | BELOXEPIN AND ANALOGS FOR THE TREATMENT OF PAIN | OPRL1, LPXN, OPRK1 | VKORC1 1655/4885CYP2C9 1314/4885ALB 4051/4885 |
| US-20190111036-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | AR, KLK3, SHBG | VKORC1 3123/4885CYP2C9 1871/4885ALB 2280/4885 |
| US-20060062859-A1 | Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes | SLC5A6, SLC46A1, CYP24A1 | VKORC1 352/4885CYP2C9 463/4885ALB 750/4885 |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | VKORC1 3798/4885CYP2C9 4423/4885ALB 4867/4885 |
| US-20170028077-A1 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | SERPINB1, SPINT2, TMPRSS15 | VKORC1 274/4885CYP2C9 105/4885ALB 683/4885 |
| US-20090233957-A1 | (-)-BELOXEPIN AND METHODS FOR ITS SYNTHESIS AND USE | BCHE, LOX, NAPEPLD | VKORC1 699/4885CYP2C9 276/4885ALB 3371/4885 |
| US-20220054468-A9 | Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer | AR, KLK3, SHBG | VKORC1 3123/4885CYP2C9 1871/4885ALB 2280/4885 |
| US-12303497-B2 | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer | AR, KLK3, SHBG | VKORC1 1778/4885CYP2C9 2234/4885ALB 742/4885 |
| US-20240100033-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer | AR, KLK3, SHBG | VKORC1 3123/4885CYP2C9 1871/4885ALB 2280/4885 |
| US-20110257129-A1 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | DUSP3, PNP, PPP5C | VKORC1 3225/4885CYP2C9 1107/4885ALB 2562/4885 |
| US-10702508-B2 | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer | AR, KLK3, SHBG | VKORC1 3123/4885CYP2C9 1871/4885ALB 2280/4885 |
| US-20100222362-A1 | N-OXIDES OF N-PHENYL-2-PYRAMIDINE-AMINE DERIVATIVES | NUDT1, NT5C2, NOX5 | VKORC1 1734/4885CYP2C9 208/4885ALB 951/4885 |
| US-20220348574-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | VKORC1 3798/4885CYP2C9 4423/4885ALB 4867/4885 |
| US-11701366-B2 | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors | ROCK2, ROCK1, CIT | VKORC1 1364/4885CYP2C9 4852/4885ALB 4424/4885 |
| US-20050033056-A1 | Hydroxylated indole derivatives and uses thereof | TPH2, TPH1, HTR6 | VKORC1 3717/4885CYP2C9 245/4885ALB 4376/4885 |
| US-20120108623-A1 | BELOXEPIN AND ANALOGS FOR THE TREATMENT OF PAIN | OPRL1, LPXN, OPRK1 | VKORC1 1655/4885CYP2C9 1314/4885ALB 4051/4885 |
| US-20230190722-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | AR, KLK3, SHBG | VKORC1 1778/4885CYP2C9 2234/4885ALB 742/4885 |
| US-20110294820-A1 | N-Oxides of n-Phenyl-2-pyrimidine-amine Derivatives | NUDT1, PNP, NME2 | VKORC1 1188/4885CYP2C9 198/4885ALB 633/4885 |
| US-20050209452-A1 | Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | MKI67, CDK4, NME2 | VKORC1 2371/4885CYP2C9 2330/4885ALB 496/4885 |
| US-11963952-B2 | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer | AR, KLK3, SHBG | VKORC1 1778/4885CYP2C9 2234/4885ALB 742/4885 |
| US-20100197797-A1 | METHODS OF MANAGING FIBROMYALGIA USING MILNACIPRAN | LPXN, MTPN, IL5 | VKORC1 955/4885CYP2C9 458/4885ALB 707/4885 |
| US-20110195940-A1 | Protease Inhibitors Having Enhanced Features | CYP3A43, HPN, ANPEP | VKORC1 583/4885CYP2C9 28/4885ALB 658/4885 |
| US-20240165091-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | AR, KLK3, SHBG | VKORC1 1778/4885CYP2C9 2234/4885ALB 742/4885 |
| US-20140323494-A1 | N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NUDT1, PNP, NME2 | VKORC1 1293/4885CYP2C9 227/4885ALB 587/4885 |
| US-11591331-B2 | PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | VKORC1 3798/4885CYP2C9 4423/4885ALB 4867/4885 |
| US-20090239879-A1 | N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NUDT1, PNP, NME2 | VKORC1 1188/4885CYP2C9 198/4885ALB 633/4885 |
| US-20090233958-A1 | (+)-BELOXEPIN AND METHODS FOR ITS SYNTHESIS AND USE | BCHE, ACHE, LOX | VKORC1 665/4885CYP2C9 281/4885ALB 3079/4885 |
| US-20110105552-A1 | BELOXEPIN AND ANALOGS FOR THE TREATMENT OF PAIN | OPRL1, LPXN, OPRK1 | VKORC1 1655/4885CYP2C9 1314/4885ALB 4051/4885 |
| US-20200352926-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer | AR, KLK3, SHBG | VKORC1 3123/4885CYP2C9 1871/4885ALB 2280/4885 |
| US-20200360361-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer | AR, KLK3, SHBG | VKORC1 3123/4885CYP2C9 1871/4885ALB 2280/4885 |
| US-11903937-B2 | — | AR, KLK3, BRDT | VKORC1 2296/4885CYP2C9 2165/4885ALB 2030/4885 |
| US-20240139211-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | SLC16A1, SLC1A1, SLC6A1 | VKORC1 4057/4885CYP2C9 3114/4885ALB 1206/4885 |
| US-20180353609-A1 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | SERPINB1, SPINT2, TMPRSS15 | VKORC1 274/4885CYP2C9 105/4885ALB 683/4885 |
| US-20050288375-A1 | Method and composition for treating neurodegenerative disorders | GRIN2A, GRIN2B, GRIN3A | VKORC1 199/4885CYP2C9 56/4885ALB 3093/4885 |
| US-20150272935-A1 | Use of a Factor Xa Inhibitor for Treating and Preventing Bleeding Events And Related Disorders in Patients Having Sensitivity to Vitamin K Antagonists Used As Anticoagulants | VKORC1, VKORC1L1, PROC | VKORC1 1/4885CYP2C9 29/4885ALB 4742/4885 |
| US-20060270638-A1 | Delivery of tigecycline in the presence of warfarin | DHFR, TNNT2, TET1 | VKORC1 44/4885CYP2C9 418/4885ALB 2058/4885 |
| US-20080213217-A1 | Enantiomerically pure phosphoindoles as HIV inhibitors | DUSP3, PNP, PPP5C | VKORC1 3225/4885CYP2C9 1107/4885ALB 2562/4885 |
| US-20210093620-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer | AR, KLK3, SHBG | VKORC1 3123/4885CYP2C9 1871/4885ALB 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.